Rosetta Genomics files $39M IPO registration

Israel's Rosetta Genomics--which is developing new therapies and diagnostics based on microRNAs--has filed an IPO in the U.S. designed to raise up to $39 million from the sale of three million shares. Shares will be priced at $11 to $13 each. C.E. Unterberg, Towbin, is acting as the lead manager and the sole bookrunner for this offering. Oppenheimer & Co. and Maxim Group are co-managers for this offering.

- here's the release on the IPO